Pioneering Japan Approval For Daiichi’s Oncolytic Virus In Glioma
But Conditions Apply
Executive Summary
Japan grants ground-breaking approval for Daiichi oncolytic virus in brain cancer on condition of additional data. The nod marks another step forward in the firm's strategic global pivot to oncology.